Format

Send to

Choose Destination
Pneumologie. 2017 Mar;71(3):151-163. doi: 10.1055/s-0042-123803. Epub 2017 Feb 14.

[Liquid Biopsy: Detection of Molecular Markers for Treatment Decisions in Lung Cancer].

[Article in German]

Author information

1
Universitätsklinik für Pneumologie, Allergologie und Schlafmedizin, Paracelsus Medizinische Privatuniversität, Nürnberg.
2
Institut für Pathologie, St. Elisabeth Krankenhaus, Köln.
3
Universitätsinstitut für Klinische Chemie, Laboratoriumsmedizin und Transfusionsmedizin - Zentrallaboratorium, Paracelsus Medizinische Privatuniversität, Nürnberg.
4
Pathologisches Institut der Ludwig-Maximilians Universität München.

Abstract

Personalized, individualized, targeted therapy has successfully found entrance in the palliative treatment of lung cancer as they enable a personalized and individualized strategy going ahead with biomarker testing. Due to the crescending amount of predictive molecular and immunhistochemical analyses at different time points during therapy the need for more and actual tumor tissue increases; however these samples cannot always be obtained without major discomfort for the patients. Therefore, analyses from blood, the so called "liquid biopsy", is an alternative or additional method. Activating mutations in the EGFR gene and the inhibitory mutation T790 M can already be detected from blood during clinical routine. This review presents the status of liquid biopsy for diagnosis, prognosis and as predictive parameter during the course of therapy in lung cancer and gives an outlook on future developments.

PMID:
28196386
DOI:
10.1055/s-0042-123803
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center